| Binding of hepatitis C virus to CD81 P Pileri, Y Uematsu, S Campagnoli, G Galli, F Falugi, R Petracca, ... Science 282 (5390), 938-941, 1998 | 2845 | 1998 |
| A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. D Rosa, S Campagnoli, C Moretto, E Guenzi, L Cousens, M Chin, C Dong, ... Proceedings of the National Academy of Sciences 93 (5), 1759-1763, 1996 | 479 | 1996 |
| Antigen-independent activation of naive and memory resting T cells by a cytokine combination. D Unutmaz, P Pileri, S Abrignani The Journal of experimental medicine 180 (3), 1159-1164, 1994 | 446 | 1994 |
| Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. MA Minutello, P Pileri, D Unutmaz, S Censini, G Kuo, M Houghton, ... The Journal of experimental medicine 178 (1), 17-25, 1993 | 288 | 1993 |
| Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults SE Frey, M Houghton, S Coates, S Abrignani, D Chien, D Rosa, P Pileri, ... Vaccine 28 (38), 6367-6373, 2010 | 285 | 2010 |
| Association of hepatitis C virus envelope proteins with exosomes F Masciopinto, C Giovani, S Campagnoli, L Galli‐Stampino, P Colombatto, ... European journal of immunology 34 (10), 2834-2842, 2004 | 256 | 2004 |
| Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes KG Hadlock, RE Lanford, S Perkins, J Rowe, Q Yang, S Levy, P Pileri, ... Journal of virology 74 (22), 10407-10416, 2000 | 248 | 2000 |
| Extremely potent human monoclonal antibodies from COVID-19 convalescent patients E Andreano, E Nicastri, I Paciello, P Pileri, N Manganaro, G Piccini, ... Cell 184 (7), 1821-1835. e16, 2021 | 191 | 2021 |
| Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein HC Song, MY Seo, K Stadler, BJ Yoo, QL Choo, SR Coates, Y Uematsu, ... Journal of virology 78 (19), 10328-10335, 2004 | 178 | 2004 |
| Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants E Andreano, I Paciello, G Piccini, N Manganaro, P Pileri, I Hyseni, ... Nature 600 (7889), 530-535, 2021 | 132 | 2021 |
| Helicobacter pylori-specific CD4+ T-cell clones from peripheral blood and gastric biopsies A Di Tommaso, Z Xiang, M Bugnoli, P Pileri, N Figura, PF Bayeli, ... Infection and immunity 63 (3), 1102-1106, 1995 | 129 | 1995 |
| Method for the preparation of purified HCV RNA by exosome separation S Abrignani, P Pileri US Patent 7,198,923, 2007 | 98* | 2007 |
| Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G. A Podda, L Nencioni, MT De Magistris, A Di Tommaso, P Bossu, S Nuti, ... The Journal of experimental medicine 172 (3), 861-868, 1990 | 90 | 1990 |
| The small extracellular loop of CD81 is necessary for optimal surface expression of the large loop, a putative HCV receptor F Masciopinto, S Campagnoli, S Abrignani, Y Uematsu, P Pileri Virus Research 80 (1-2), 1-10, 2001 | 67 | 2001 |
| Angiopoietin-like 7, a novel pro-angiogenetic factor over-expressed in cancer M Parri, L Pietrovito, A Grandi, S Campagnoli, E De Camilli, F Bianchini, ... Angiogenesis 17, 881-896, 2014 | 65 | 2014 |
| Magnetically driven drug delivery systems improving targeted immunotherapy for colon-rectal cancer R Grifantini, M Taranta, L Gherardini, I Naldi, M Parri, A Grandi, ... Journal of Controlled Release 280, 76-86, 2018 | 48 | 2018 |
| T cell receptor γδ repertoire is skewed in cerebrospinal fluid of multiple sclerosis patients: molecular and functional analyses of antigen‐reactive γδ clones S Nick, P Pileri, S Tongiani, Y Uematsu, L Kappos, G De Libero European journal of immunology 25 (2), 355-363, 1995 | 48 | 1995 |
| Immunostimulation by a partially modified retro-inverso-tuftsin analog containing Thr1. sum.. psi.[NHCO](R, S) Lys2 modification AS Verdini, S Silvestri, C Becherucci, MG Longobardi, L Parente, ... Journal of medicinal chemistry 34 (12), 3372-3379, 1991 | 42 | 1991 |
| FAT1: a potential target for monoclonal antibody therapy in colon cancer P Pileri, S Campagnoli, A Grandi, M Parri, E De Camilli, C Song, L Ganfini, ... British journal of cancer 115 (1), 40-51, 2016 | 38 | 2016 |
| Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody JL Torres, G Ozorowski, E Andreano, H Liu, J Copps, G Piccini, L Donnici, ... Proceedings of the National Academy of Sciences 119 (20), e2120976119, 2022 | 26 | 2022 |
